Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 6/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15578975 | 0.79 | GSK3A (0.40) | GSK3AGSK3BLPLLIPGDGAT1 | |
| SCHEMBL10565 | 0.78 | CDK8 (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL30082544 | 0.78 | CDK8 (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL2969113 | 0.78 | BRD4 (0.43) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL15751423 | 0.77 | GSK3A (0.38) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL25431172 | 0.76 | GSK3A (0.42) | GSK3AGSK3BPDGFRBKDRALPL | |
| SCHEMBL10475 | 0.76 | NOS1 (0.45) | GSK3BKDRLPLLIPGIRAK4 | |
| SCHEMBL31620771 | 0.75 | TRPA1 (0.40) | GSK3AGSK3BLPLLIPGFFAR1 | |
| SCHEMBL20085466 | 0.75 | TRPA1 (0.40) | GSK3AGSK3BLPLLIPGFFAR1 | |
| SCHEMBL16722737 | 0.74 | NOS1 (0.39) | GSK3AGSK3BLPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025101914-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS | MEKANISTIC THERAPEUTICS LLC (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| EP-2485731-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| WO-2009114870-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GSK3A 630/4885GSK3B 636/4885PDGFRB 2511/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GSK3A 630/4885GSK3B 636/4885PDGFRB 2511/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | GSK3A 3257/4885GSK3B 3383/4885PDGFRB 2894/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | GSK3A 3075/4885GSK3B 3128/4885PDGFRB 4811/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | GSK3A 331/4885GSK3B 349/4885PDGFRB 726/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | GSK3A 2003/4885GSK3B 1719/4885PDGFRB 2310/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | GSK3A 4487/4885GSK3B 4424/4885PDGFRB 4441/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | GSK3A 4013/4885GSK3B 3808/4885PDGFRB 3336/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | GSK3A 4013/4885GSK3B 3808/4885PDGFRB 3336/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | GSK3A 2618/4885GSK3B 3324/4885PDGFRB 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.